Becton Dickinson logo

Becton Dickinson AI Adoption Tracker

Last updated: August 9, 2026

3.3 Good

Overview

Becton Dickinson (BD) has emerged as a strategic AI adopter in the medical technology sector, positioning AI as central to its transformation into a 'pure-play MedTech leader.' BD launched the BD Incada™ Connected Care Platform in October 2025, an AI-enabled, cloud-based platform that unifies data from nearly 3 million connected BD devices into one intelligent ecosystem[1][2]. The company has developed AI-powered solutions across multiple business areas, including the BD Kiestra™ MRSA application for laboratory automation with AI-assisted plate reading[3], the BD HealthSight™ Diversion Management software using advanced AI to detect controlled substance diversion in operating rooms[4], and strategic partnerships like the collaboration with Techcyte for AI-based digital cervical cytology systems[5]. Under CEO Tom Polen's leadership, BD has positioned 2025 as a pivotal year for leveraging 'significant shifts in technology, like biologics, AI and automation, that are revolutionizing patient care'[6].

AI Maturity Index

3.3 /5 Practitioner

Evidence high

  • AI deployed across medication management, laboratory automation, patient monitoring per platform launches [corporate]
  • Nearly 3 million connected devices with AI capabilities [corporate]

Missing Evidence

  • Limited AI hiring signals in job postings suggest workforce not scaling with AI ambitions

Evidence medium

  • CEO Tom Polen positions AI as core to transformation strategy [news]
  • CTO Beth McCombs leads R&D organization with AI focus [news]

Missing Evidence

  • Very low non-tech AI hiring (1.7%) suggests limited workforce AI fluency
  • No evidence of comprehensive AI training programs

Evidence medium

  • 9.8 million daily transactions processed through AI-enabled medication management systems [corporate]
  • 27 AI patents filed in Q2 2024 indicating innovation pipeline [news]

Missing Evidence

  • No specific ROI figures or cost savings quantified in public sources
  • Limited evidence of AI impact on financial performance

Radar Comparison

Company Sector Avg

Peer Comparison: Becton Dickinson vs healthcare

Based on 66 companies in sector

Dimension Becton Dickinson Sector Avg Diff
Adoption 4.0 3.7 +0.3
Proficiency 3.0 3.5 -0.5
Impact 3.0 3.6 -0.6
Overall 3.3 3.6 -0.3

AI Hiring Signals

Becton Dickinson Job Postings Analysis

1.4%
AI Mention Rate
144
Jobs Sampled
2
AI-Related Jobs
High Confidence
Data Quality

Tech vs Non-Tech AI Requirements

Tech Roles (Engineering/Data) 0.0%
Non-Tech Roles 1.7%

Non-tech AI adoption exceeds tech roles - strong org-wide AI fluency signal

Top Departments by AI Mention Rate

Product
8.3%
Finance
7.1%
Engineering/Tech
0.0%

Analysis

BD shows minimal AI hiring emphasis with only 1.4% of job postings mentioning AI. Notably, tech roles show 0% AI mentions while non-tech roles show 1.7%, suggesting AI adoption is primarily driven by business functions rather than core technology teams.

View Sample Job Postings (5 sources)

Key Metrics

Nearly 3 million smart connected BD devices
Connected devices supported
Source: https://investors.bd.com/news-events/press-releases/detail/910/bd-launches-new-ai-enabled-solutions-to-drive-connectivity-across-healthcare-settings
More than 9.8 million transactions on BD Pyxis™ devices every day
Daily medication management transactions
Source: https://investors.bd.com/news-events/press-releases/detail/910/bd-launches-new-ai-enabled-solutions-to-drive-connectivity-across-healthcare-settings
27 patents in artificial intelligence during Q2 2024
AI patent portfolio
Source: https://www.medicaldevice-network.com/data-insights/becton-dickinson-and-co-in-artificial-intelligence-theme-innovation-strategy/
6
AI Initiatives
Source: Larridin Analysis

AI Initiatives

1

BD Incada™ Connected Care Platform

October 20, 2025

Active

AI-enabled, cloud-based platform that unifies BD device data into one intelligent ecosystem

Built on AWS infrastructure with natural language analytics, scalable to meet data volumes from nearly 3 million smart connected BD devices. Provides enterprise-wide visibility into medication inventory with AI-powered insights and customizable dashboards.

2

HemoSphere Alta™ Advanced Monitoring Platform

April 21, 2025

Active

Next-generation hemodynamic monitoring with AI-driven clinical decision support

Features predictive AI algorithms to help clinicians proactively address blood pressure instability and optimize blood flow during critical procedures.

3

BD HealthSight™ Diversion Management with AI

September 26, 2024

Active

Advanced AI software to detect controlled substance diversion in operating rooms

Uses artificial intelligence to identify patterns and indicators of controlled substance diversion by healthcare workers, particularly effective in operating room environments.

4

BD Advanced Patient Monitoring with AI

September 3, 2024

Active

Integration of AI-enabled clinical decision tools through Edwards Lifesciences acquisition

Acquired Edwards' Critical Care product group including advanced AI algorithm clinical decision support tools for smart connected care solutions.

5

BD-Techcyte AI Cervical Cytology Collaboration

January 30, 2024

Active

Strategic partnership for AI-based digital cervical cytology system

AI algorithm guides cytologists and pathologists to efficiently identify evidence of cervical cancer and precancer using whole-slide imaging, reducing human error and enabling greater throughput.

Frequently Asked Questions

BD Incada™ Connected Care Platform is BD's AI-enabled, cloud-based platform that unifies data from nearly 3 million BD devices into one intelligent ecosystem, launched in October 2025.

BD uses AI through the HealthSight™ Diversion Management software to detect controlled substance diversion and the Incada™ platform to provide enterprise-wide visibility into medication inventory with AI-powered insights.

BD's Kiestra™ MRSA application uses AI-powered computer vision to automatically triage bacterial culture plates, distinguishing between plates with no growth versus those requiring technician attention.

Yes, BD acquired Edwards Lifesciences' Critical Care product group in September 2024, which includes advanced AI algorithm clinical decision support tools for patient monitoring.

Key partnerships include Techcyte for AI-based cervical cytology systems, AWS for cloud infrastructure, and Mayo Clinic Platform for AI/ML-powered post-market surveillance using real-world data.

Related Companies

About AI Tracker

AI Tracker is a research project by Larridin, the AI execution intelligence platform.

Methodology: We analyze earnings calls, press releases, partnership announcements, and product documentation. All assessments are based solely on publicly available information—no private customer data is used.

Maturity Scoring: Each dimension is rated on a 4-tier scale (Nascent → Emerging → Scaling → Leading) based on evidence from public sources. Industry averages are computed as the median across all tracked companies in the sector.

Update cadence: Every 2-3 weeks
Last updated: August 9, 2026